Buccal insulin for the management of type 1 diabetes
Please note that this topic has now been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 311
Referral date 01 February 2010
Topic area
  • Endocrine, nutritional and metabolic

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 January 2024 Discontinued. Please note that this topic has now been discontinued.
28 July 2011

As you are aware, the Department of Health has asked us to carry out a single technology appraisal of buccal insulin within its licensed indication for the management of type 1 diabetes as part of our 22nd wave work programme.

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.


For further information on our processes and methods, please see our CHTE processes and methods manual